| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/11/2001 | DE10015866A1 Aryl- und Heteroarylsulfonate Aryl and Heteroarylsulfonate |
| 10/11/2001 | DE10015814A1 Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung Medicines to stimulate leukopoiesis, for the treatment of tumors and protozoal diseases and process for its preparation |
| 10/11/2001 | DE10015783A1 Transdermales therapeutisches System zur Abgabe von Lerisetron Transdermal therapeutic system for the delivery of lerisetron |
| 10/11/2001 | DE10011883A1 New non-solvated crystalline form of fluorinated estratriene-diol derivative, useful as antiestrogen e.g. for treating breast or endometrial cancer, chemotherapy-induced alopecia, endometriosis or anovulatory infertility |
| 10/11/2001 | CA2413211A1 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 10/11/2001 | CA2405549A1 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcription coupled repair genes |
| 10/11/2001 | CA2405496A1 Vasopeptidase inhibitors to treat isolated systolic hypertension |
| 10/11/2001 | CA2405293A1 Topical compositions containing prostaglandin e1 |
| 10/11/2001 | CA2405132A1 2-hydroxy-mutilin carbamate derivatives for antibacterial use |
| 10/11/2001 | CA2405126A1 Novel 1,2,3,4-tetrahydrosioquinoline, their preparation method and their use as fungicides |
| 10/11/2001 | CA2405099A1 Composition and method for promoting oral health |
| 10/11/2001 | CA2405043A1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 10/11/2001 | CA2404896A1 Human ion channel protein and polynucleotides encoding the same |
| 10/11/2001 | CA2404890A1 Rna sequence-specific mediators of rna interference |
| 10/11/2001 | CA2404687A1 Sustained release beadlets containing stavudine |
| 10/11/2001 | CA2404665A1 Novel compounds for enhancing chemotherapy |
| 10/11/2001 | CA2404628A1 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds |
| 10/11/2001 | CA2404592A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 10/11/2001 | CA2404545A1 Aryl and heteroaryl sulfonates |
| 10/11/2001 | CA2404526A1 Protein amf-1 to amf-10 and nucleic acids encoding the same |
| 10/11/2001 | CA2404519A1 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 10/11/2001 | CA2404484A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| 10/11/2001 | CA2404475A1 Phenylsulphonylpiperazinyl derivatives as 5-ht receptor ligands |
| 10/11/2001 | CA2404413A1 Small organic molecule regulators of cell proliferation |
| 10/11/2001 | CA2404386A1 Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain |
| 10/11/2001 | CA2404376A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 10/11/2001 | CA2404373A1 O-aryl glucoside sglt2 inhibitors and method |
| 10/11/2001 | CA2404367A1 Pharmaceutical preparations and their manufacture |
| 10/11/2001 | CA2404365A1 Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| 10/11/2001 | CA2404358A1 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
| 10/11/2001 | CA2404350A1 Control of a gene induced by oxidized lipids in human artery wall cells |
| 10/11/2001 | CA2404314A1 Succinoylamino heterocycles as inhibitors of a.beta. protein production |
| 10/11/2001 | CA2404312A1 Chemokine receptor antagonists |
| 10/11/2001 | CA2404298A1 Amiodarone-containing parenteral solution |
| 10/11/2001 | CA2404291A1 Butylnitrone containing compositons for inhibition of cancer development |
| 10/11/2001 | CA2404040A1 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 10/11/2001 | CA2404023A1 Cyclic lactams as inhibitors of a.beta. protein production |
| 10/11/2001 | CA2403991A1 Aminopyridines and their use as anticonvulsants and sodium channel blockers |
| 10/11/2001 | CA2403958A1 Pharmaceutical kit comprising midodrine as an active drug substance |
| 10/11/2001 | CA2403950A1 Treatment of renal disorders |
| 10/11/2001 | CA2403886A1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine |
| 10/11/2001 | CA2403885A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist |
| 10/11/2001 | CA2403791A1 Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels |
| 10/11/2001 | CA2403735A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase |
| 10/11/2001 | CA2403635A1 Crystalline hydrated lopinavir |
| 10/11/2001 | CA2403612A1 Improved treatment of neovascularization |
| 10/11/2001 | CA2403608A1 Use of fulvestrant in the treatment of resistant breast cancer |
| 10/11/2001 | CA2403600A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain |
| 10/11/2001 | CA2403550A1 Cyclic lactams as inhibitors of a-.beta. protein production |
| 10/11/2001 | CA2403537A1 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 10/11/2001 | CA2403160A1 New combination of a betablocker and a cholesterol-lowering agent |
| 10/11/2001 | CA2402864A1 D and l etherlipid stereoisomers and liposomes |
| 10/11/2001 | CA2402705A1 Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain |
| 10/11/2001 | CA2402539A1 Combination therapies with vascular damaging activity |
| 10/11/2001 | CA2402078A1 Divided dose therapies with vascular damaging activity |
| 10/11/2001 | CA2401888A1 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 10/11/2001 | CA2401854A1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 10/11/2001 | CA2401269A1 Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins |
| 10/11/2001 | CA2401137A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| 10/11/2001 | CA2401112A1 Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera |
| 10/11/2001 | CA2401104A1 Method for treating cells resistant to antineoplastic agents |
| 10/11/2001 | CA2400057A1 4-oxo-1,4-dihydro¬1,8|naphthyridine-3-carboxamides as antiviral agents |
| 10/11/2001 | CA2399399A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| 10/11/2001 | CA2399275A1 Novel benzosultam oxazolidinone antibacterial agents |
| 10/11/2001 | CA2397203A1 Phosphoramidate prodrugs |
| 10/11/2001 | CA2393788A1 .beta.3-adrenoreceptor agonists, agonist compositions and methods of making and using the same |
| 10/11/2001 | CA2368966A1 New derivatives and analogues of galanthamine |
| 10/10/2001 | EP1143004A2 Bacillus thuringiensis microbes active against nematodes, and genes encoding novel nematode-active toxins cloned from bacillus thuringiensis isolates |
| 10/10/2001 | EP1142910A1 Inhibitors for the formation of soluble human CD23 |
| 10/10/2001 | EP1142903A1 BRAIN CELL OR NERVE CELL-PROTECTIVE AGENTS COMPRISING GINSENOSIDE Rb 1? |
| 10/10/2001 | EP1142902A2 3'-Derivatised oligonucleotide analogues with non-nucleotidic groups, their preparation and use |
| 10/10/2001 | EP1142893A1 Substituted O6-benzylguanines and 6(4)-benzyloxypyrimidines |
| 10/10/2001 | EP1142891A1 Use of 5-Fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B |
| 10/10/2001 | EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents |
| 10/10/2001 | EP1142886A1 Percyquinnin, a process for its production and its use as a pharmaceutical |
| 10/10/2001 | EP1142881A1 Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives |
| 10/10/2001 | EP1142879A1 Imidazole compounds and medicinal use thereof |
| 10/10/2001 | EP1142878A2 Pharmaceutical compositions comprising moexipril magnesium |
| 10/10/2001 | EP1142872A1 Aromatic heterocycle compounds having hiv integrase inhibiting activities |
| 10/10/2001 | EP1142870A1 Novel ligands of nuclear receptor |
| 10/10/2001 | EP1142867A2 Cell adhesion inhibitors |
| 10/10/2001 | EP1142587A1 Remedies for pain |
| 10/10/2001 | EP1142586A1 Inhibitors against vascular lipid deposition containing chymase-inhibiting substances |
| 10/10/2001 | EP1142585A1 Remedies for corneal disorders |
| 10/10/2001 | EP1142584A1 Compositions for treating frequent urination and urinary incontinence |
| 10/10/2001 | EP1142583A1 Antitumor agents |
| 10/10/2001 | EP1142581A2 Tissue sealant and growth factor containing compositions that promote accelerated wound healing |
| 10/10/2001 | EP1142580A1 Use of peptide |
| 10/10/2001 | EP1142579A2 Bone resorption inhibitors |
| 10/10/2001 | EP1142578A1 Method for producing an antitumoral agent and antitumoral agent thus obtained |
| 10/10/2001 | EP1142577A2 Method of treating a parasitic infection |
| 10/10/2001 | EP1142576A1 Drug compositions for the treatment of ocular hypertension or glaucoma |
| 10/10/2001 | EP1142575A1 Dry skin remedies |
| 10/10/2001 | EP1142574A1 Pharmaceutical formulations comprising amoxycillin and clavulanate |
| 10/10/2001 | EP1142573A1 Antibacterial medicinal compositions |
| 10/10/2001 | EP1142572A1 Oxetanone-containing preparations for the treatment of intestinal illnesses |
| 10/10/2001 | EP1142571A1 Method to produce solid creatine dosage forms and dosage forms thus obtained |
| 10/10/2001 | EP1142570A1 Angiogenesis inhibitor |
| 10/10/2001 | EP1142566A1 Compositions for ophtalmic use containing cyclosporin, hyaluronic acid and polysorbate |
| 10/10/2001 | EP1142565A1 Aqueous medicinal compositions |